People with refractory myasthenia gravis (MG) who fail to respond to several treatments may be effectively treated with Vyvgart (efgartigimod alfa-fcab), regardless of the type of self-reactive antibodies they carry. That’s according to a systematic review and meta-analysis, which showed that patients treated with Vyvgart saw their symptoms…
Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis (gMG) when used in everyday clinical practice. That’s according to data from the MG SPOTLIGHT Registry (NCT04202341), which was established to assess the long-term effectiveness of both therapies in…
Treatment with the experimental injection therapy claseprubart (DNTH103) was well tolerated and appeared to ease symptoms of generalized myasthenia gravis (gMG) in a Phase 2 clinical trial involving people with the autoimmune neuromuscular condition. That’s according to top-line data announced by the therapy’s developer Dianthus Therapeutics. The…
An analysis of the Swedish MG registry suggests that adults with myasthenia gravis (MG) have an impaired quality of life, even when they show low disease activity. Muscle weakness affecting the limbs and breathing primarily drove a diminished quality of life. These findings indicate “an unmet medical need that…
A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path to [regulatory approval]” — is expected to start enrolling participants before the end of the year, according to…
Cemdisiran, an under-the-skin injection therapy given every three months, significantly reduced disease activity in people with generalized myasthenia gravis (gMG) after six months of treatment. That’s according to data from the Regeneron Pharmaceuticals-sponsored Phase 3 NIMBLE study (NCT05070858), which evaluated cemdisiran as a monotherapy, as well as…
Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily living among adults who tested negative for antibodies targeting the acetylcholine receptor (AChR) — the most common cause of the disease. That’s according to top-line data from an ongoing Phase 3…
Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune response — might help keep myasthenia gravis (MG) under control. That’s according to the findings of a new study from China using immune cells from patients, which suggested that…
Rituximab may be safe and effective in treating women with myasthenia gravis (MG) that’s driven by antibodies that target muscle-specific tyrosine kinase (MuSK), an analysis of patients at a single center in China shows. Significant symptom relief was seen by 90% of patients after a month of treatment and it…
Nine-time tennis Grand Slam champion Monica Seles, who has myasthenia gravis (MG), is teaming up with pharmaceutical company Argenx on a campaign aimed at raising awareness — and increasing understanding — of the rare neuromuscular disease. “I am excited to partner with the Argenx team — to inspire…
Get regular updates to your inbox.
